Danish biotechnology company Genmab A/S (CPH: GMAB) has entered into a definitive agreement to acquire EQT Life Sciences portfolio company Merus N.V. (NASDAQ: MRUS) in an all-cash transaction valued at USD8bn, EQT Life Sciences announced on Tuesday.
Merus, headquartered in Utrecht, the Netherlands, is a clinical-stage oncology company developing bispecific and trispecific antibody therapeutics. Its pipeline includes petosemtamab, in development for head and neck squamous cell carcinoma and other malignancies, and zenocutuzumab, an approved therapy for NRG1 fusion-driven tumours such as pancreatic and lung cancers.
EQT Life Sciences says that Petosemtamab has demonstrated best-in-class Phase 2 results in head and neck cancer, significantly outperforming historical benchmarks. The drug has received two FDA Breakthrough Therapy Designations, with additional trials ongoing in colorectal cancer.
EQT Life Sciences has been an investor in Merus since 2010, supporting its growth from a small preclinical start-up to a NASDAQ-listed biotech with more than 300 employees.
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe